Eliquis 5mg

Indications for use

treatment of venous thrombosis and pulmonary embolism;
prevention of thromboembolism in case if atrial fibrillation in the background of stroke, hypertension, heart failure, diabetes;
prevention of thrombosis after joint replacement of the lower extremities.

Method of reception and dosage

The pills of Eliquis are taken orally. Dosage depends on the disease.
Eliquis 5 mg is prescribed after a scheduled arthroplasty twice a day and you should start taking in 12 h after the procedure. The duration of treatment is 38 days for hip replacement and 14 days for knee replacement.
If you suffer from atrial fibrillation, you should take 5 mg of the drug 2 times a day. If your weight is less than 60 kg and you are less than 80 years old — you should take 2.5 mg twice a day.
If you suffer from DVT or PATE, the drug is taken for 7 days at the dosage of 10 mg 2 times a day, followed by 5 mg twice a day.
If you want to prevent the relapses of DVT and PATE, you should take 2.5 mg 2 times a day for 6 months.

Interaction with other drugs

The combination with ketoconazole (inhibitor of CYP3A4 isoenzyme and P-glycoprotein) leads to an increase in Cmax by almost 1.6 times, but dose adjustment is not required. Diltiazem, amiodarone, naproxen, quinidine, verapamil lead to an increase in the concentration of the active substance, but to a lesser extent (1.3 -1.4 times). Dose adjustment is also not required. The use of rifampicin (inducer of CYP3A4 isoenzyme) leads to a decrease in Cmax of the active substance in the blood by 42%. The same effect can be expected when combined with phenytoin, phenobarbital and carbamazepine. The use of these drugs is not recommended in the treatment of pulmonary embolism and DVT.

The combined reception of enoxaparin and apixaban intensifies the action on FXa. There was no significant interaction with acetylsalicylic acid in healthy individuals.

The combination with clopidogrel and acetylsalicylic acid does not lead to an increase in bleeding time and coagulation system parameters remain the same as with apixaban monotherapy. However, such a triple combination of drugs is contraindicated to patients with acute coronary syndrome and concomitant diseases. If you suffer from atrial fibrillation, the triple combination also leads to the risk of bleeding.